Boehringer Ingelheim expanded its China portfolio through a cancer drug development deal with Sino Biopharmaceutical (SBP Group) that could exceed $7 billion in total payments, according to the reported terms. The agreement includes $358 million in upfront and near-term payments, with milestone opportunities reaching $7 billion on top, plus royalties. The pact is described as the second partnership between the two companies and underscores Boehringer’s continued strategy to deepen presence in preclinical oncology programs in China through large milestone-linked licensing structures.